The efficacy and safety of plasma exchange in patients with sepsis and septic shock: a systematic review and meta-analysis
详细信息 查看全文
- 作者：Emily Rimmer (1) (2)
Brett L Houston (3)
Anand Kumar (1)
Ahmed M Abou-Setta (4)
Carol Friesen (5)
John C Marshall (6)
Gail Rock (7)
Alexis F Turgeon (8)
Deborah J Cook (10) (9)
Donald S Houston (1) (2)
Ryan Zarychanski (1) (2) (4)
1. Department of Internal Medicine ; University of Manitoba ; GC425-820 Sherbrook Street ; HSC ; Winnipeg ; R3A 1R9 ; Canada
2. Department of Haematology and Medical Oncology ; CancerCare Manitoba ; 675 McDermot Ave ; Winnipeg ; R3E 0V9 ; Canada
3. Faculty of Medicine ; University of Manitoba ; 250 Brodie Centre ; 727 McDermot Ave ; Winnipeg ; R3E 3P5 ; Canada
4. George & Fay Yee Center for Healthcare Innovation ; University of Manitoba/Winnipeg Regional Health Authority ; GE706-820 Sherbrook Street ; HSC ; Winnipeg ; R3A 1R9 ; Canada
5. Neil John Maclean Health Sciences Library ; University of Manitoba ; Brodie Centre ; 727 McDermot Ave ; Winnipeg ; R3E 3P5 ; Canada
6. Section of Critical Care Medicine ; St. Michael鈥檚 Hospital ; 30 Bond Street ; Toronto ; M5B 1W8 ; Canada
7. Ottawa Hospital ; 501 Smyth Road ; Ottawa ; K1H 8L6 ; Canada
8. Division of Critical Care Medicine ; Department of Anesthesiology and Critical Care Medicine and Population Health and Optimal Health Practices Unit ; CHU de Qu茅bec Research Center ; Universit茅 Laval ; 1401-18th Street ; Qu茅bec ; G1J 1Z4 ; Canada
10. Department of Clinical Epidemiology and Biostatistics ; McMaster University ; 1280 Main Street ; West ; Hamilton ; Canada
9. Department of Medicine ; McMaster University ; Hamilton ; L8S 4K1 ; Canada - 刊名：Critical Care
- 出版年：2014
- 出版时间：December 2014
- 年：2014
- 卷：18
- 期：6
- 全文大小：912 KB
- 参考文献：1. Angus, DC, Poll, T (2013) Severe sepsis and septic shock. N Engl J Med 369: pp. 840-851 CrossRef
2. Brun-Buisson, C, Doyon, F, Carlet, J, Dellamonica, P, Gouin, F, Lepoutre, A, Mercier, JC, Offenstadt, G, Regnier, B (1995) Incidence, risk factors, and outcome of severe sepsis and septic shock in adults: a multicenter prospective study in intensive care units. JAMA 274: pp. 968 CrossRef
3. Schoenberg, MH, Weiss, M, Radermacher, P (1998) Outcome of patients with sepsis and septic shock after ICU treatment. Langenbecks Arch Surg 383: pp. 44-48 CrossRef
4. Martin, GS, Mannino, DM, Eaton, S, Moss, M (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348: pp. 1546-1554 CrossRef
5. Fortenberry, JD, Paden, ML (2006) Extracorporeal therapies in the treatment of sepsis: experience and promise. Semin Pediatr Infect Dis 17: pp. 72-79 CrossRef
6. Szczepiorkowski, ZM, Winters, JL, Bandarenko, N, Kim, HC, Linenberger, ML, Marques, MB, Sarode, R, Schwartz, J, Weinstein, R, Shaz, BH (2010) Apheresis Applications Committee of the American Society for A: Guidelines on the use of therapeutic apheresis in clinical practice 鈥?evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 25: pp. 83-177 CrossRef
7. Stegmayr, B (2008) Apheresis in patients with severe sepsis and multi organ dysfunction syndrome. Transfus Apher Sci 38: pp. 203-208 CrossRef
8. Vain, NE, Mazlumian, JR, Swarner, OW, Cha, CC (1980) Role of exchange transfusion in the treatment of severe septicemia. Pediatrics 66: pp. 693-697
9. Bjorvatn, B, Bjertnaes, L, Fadnes, HO, Flaegstad, T, Gutteberg, TJ, Kristiansen, BE, Pape, J, Rekvig, OP, Osterud, B, Aanderud, L (1984) Meningococcal septicaemia treated with combined plasmapheresis and leucapheresis or with blood exchange. Br Med J 288: pp. 439-441 CrossRef
10. Brandtzaeg, P, Sirnes, K, Folsland, B (1985) Plasmapheresis in the treatment of severe meningococcal or pneumococcal septicaemia with DIC and fibrinolysis. Preliminary data on eight patients. Scand J Clin Lab Invest 45: pp. 53-55
11. Drapkin, MS, Wisch, JS, Gelfand, JA, Cannon, JG, Dinarello, CA (1989) Plasmapheresis for fulminant meningococcemia. Pediatr Infect Dis J 8: pp. 399-400 CrossRef
12. Scharfman, WB, Tillotson, JR, Taft, EG, Wright, E (1979) Plasmapheresis for meningococcemia with disseminated intravascular coagulation. N Engl J Med 300: pp. 1277-1278
13. Schmidt, J, Mann, S, Mohr, VD, Lampert, R, Firla, U, Zirngibl, H (2000) Plasmapheresis combined with continuous venovenous hemofiltration in surgical patients with sepsis. Intensive Care Med 26: pp. 532-537 CrossRef
14. Deuren, M, Santman, FW, Dalen, R, Sauerwein, RW, Span, LFR, Meer, JWM (1992) Plasma and whole blood exchange in meningococcal sepsis. Clin Infect Dis 15: pp. 424-430 CrossRef
15. Gardlund, B, Sjolin, J, Nilsson, A, Roll, M, Wickerts, CJ, Wikstrom, B, Wretlind, B (1993) Plasmapheresis in the treatment of primary septic shock in humans. Scand J Infect Dis 25: pp. 757-761 CrossRef
16. Stegmayr, BG (1996) Plasma exchange in patients with septic shock including acute renal failure. Blood Purif 14: pp. 102-108 CrossRef
17. Chandler J, Churchill R, Higgins J, Lasserson T, Tovey D: Methodological Expectations of Cochrane Intervention Reviews (MECIR) methodological standards for the conduct of new Cochrane Intervention Reviews, Version 2.1. The Cochrane Collaboration; 2011. [www.editorial-unit.cochrane.org/mecir]
18. Moher, D, Liberati, A, Tetzlaff, J, Altman, DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339: pp. b2535 CrossRef
19. Higgins JP, Green S (Eds): / Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 edition. The Cochrance Collaboration; 2011. [www.cochrane-handbook.org]
20. Higgins JPT, Green S (Eds): / Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. The Cochrane Collaboration; 2008. [www.cochrane-handbook.org]
21. Julian, PTH, Douglas, GA, Peter, CG, Peter, J脙, David, M, Andrew, DO, Jelena, S, Kenneth, FS, Laura, W, Jonathan, ACS (2011) The Cochrane Collaboration鈩?tool for assessing risk of bias in randomised trials. BMJ 343: pp. d5928 CrossRef
22. Knaus, WA, Draper, EA (1985) APACHE II: A severity of disease classification system. Crit Care Med 13: pp. 818-829 CrossRef
23. Reeves, JH, Butt, WW, Shann, F, Layton, JE, Stewart, A, Waring, PM, Presneill, JJ (1999) Continuous plasmafiltration in sepsis syndrome. Plasmafiltration in Sepsis Study Group. Crit Care Med 27: pp. 2096-2104 CrossRef
24. Busund, R, Koukline, V, Utrobin, U, Nedashkovsky, E (2002) Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial. Intensive Care Med 28: pp. 1434-1439 CrossRef
25. Nguyen, TC, Han, YY, Kiss, JE, Hall, MW, Hassett, AC, Jaffe, R, Orr, RA, Janosky, J, Carcillo, JA (2008) Intensive plasma exchange increases a disintegrin and metalloprotease with thrombospondin motifs-13 activity and reverses organ dysfunction in children with thrombocytopenia-associated multiple organ failure. Crit Care Med 36: pp. 2878-2887 CrossRef
26. Long, EJ, Shann, F, Pearson, G, Buckley, D, Butt, W (2013) A randomised controlled trial of plasma filtration in severe paediatric sepsis. Crit Care Resusc 15: pp. 198-204
27. Aird, WC (2003) The hematologic system as a marker of organ dysfunction in sepsis. Mayo Clin Proc 78: pp. 869-881 CrossRef
28. Levy, MM, Fink, MP, Marshall, JC, Abraham, E, Angus, D, Cook, D, Cohen, J, Opal, SM, Vincent, J-L, Ramsay, G (2003) SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 31: pp. 1250-1256 CrossRef
29. Matthay, MA (2001) Severe sepsis 鈥?a new treatment with both anticoagulant and antiinflammatory properties. N Engl J Med 344: pp. 759-762 CrossRef
30. Levi, M, Schultz, M, Poll, T (2011) Coagulation biomarkers in critically ill patients. Crit Care Clin 27: pp. 281-297 CrossRef
31. Toltl, LJ, Swystun, LL, Pepler, L, Liaw, PC (2008) Protective effects of activated protein C in sepsis. Thromb Haemost 100: pp. 582-592
32. Afshari, A, Wetterslev, J, Brok, J, Moller, A (2007) Antithrombin III in critically ill patients: systematic review with meta-analysis and trial sequential analysis. BMJ 335: pp. 1248-1251 2500.25" target="_blank" title="It opens in new window">CrossRef
33. Bernard, GR, Vincent, JL, Laterre, PF, LaRosa, SP, Dhainaut, JF, Lopez-Rodriguez, A, Steingrub, JS, Garber, GE, Helterbrand, JD, Ely, EW, Fisher, CJ (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344: pp. 699-709 CrossRef
34. Esmon, CT (2000) Introduction: are natural anticoagulants candidates for modulating the inflammatory response to endotoxin?. Blood 95: pp. 1113-1116
35. Abraham, E, Reinhart, K, Opal, S, Demeyer, I, Doig, C, Rodriguez, AL, Beale, R, Svoboda, P, Laterre, PF, Simon, S, Light, B, Spapen, H, Stone, J, Seibert, A, Peckelsen, C, Deyne, C, Postier, R, Pettila, V, Artigas, A, Percell, SR, Shu, V, Zwingelstein, C, Tobias, J, Poole, L, Stolzenbach, JC, Creasey, AA (2003) Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 290: pp. 238-247 CrossRef
36. Fisher, CJ, Dhainaut, JF, Opal, SM, Pribble, JP, Balk, RA, Slotman, GJ, Iberti, TJ, Rackow, EC, Shapiro, MJ, Greenman, RL, Reines, HD, Shelly, MP, Thompson, BW, LaBrecque, JF, Catalano, MA, Knaus, WA, Sadoff, JC, Phase, III (1994) Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 271: pp. 1836-1843 CrossRef
37. Bone, RC, Balk, RA, Fein, AM, Perl, TM, Wenzel, RP, Reines, HD, Quenzer, RW, Iberti, TJ, Macintyre, N, Schein, RM (1995) A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group. Crit Care Med 23: pp. 994-1006 CrossRef
38. Cohen, J, Carlet, J (1996) INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 24: pp. 1431-1440 CrossRef
39. Abraham, E, Wunderink, R, Silverman, H, Perl, TM, Nasraway, S, Levy, H, Bone, R, Wenzel, RP, Balk, R, Allred, R, Pennington, JE, Wherry, JC (1995) Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 273: pp. 934-941 CrossRef
40. Ronco, C, Tetta, C, Mariano, F, Wratten, ML, Bonello, M, Bordoni, V, Cardona, X, Inguaggiato, P, Pilotto, L, D鈥橧ntini, V, Bellomo, R (2003) Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis. Artif Organs 27: pp. 792-801 CrossRef
41. Rock, GA, Shumak, KH, Buskard, NA, Blanchette, VS, Kelton, JG, Nair, RC, Spasoff, RA (1991) Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 325: pp. 393-397 250604" target="_blank" title="It opens in new window">CrossRef
42. Cinel, I, Opal, SM (2009) Molecular biology of inflammation and sepsis: a primer. Crit Care Med 37: pp. 291-304 CrossRef
43. Zhou, F, Peng, Z, Murugan, R, Kellum, JA (2013) Blood purification and mortality in sepsis: a meta-analysis of randomized trials. Crit Care Med 41: pp. 2209-2220 CrossRef
44. Livigni, S, Bertolini, G, Rossi, C, Ferrari, F, Giardino, M, Pozzato, M, Remuzzi, G (2014) Efficacy of coupled plasma filtration adsorption (CPFA) in patients with septic shock: A multicenter randomised controlled clinical trial. BMJ Open 4: pp. e003536 CrossRef
45. Taori, G, Ho, KM, George, C, Bellomo, R, Webb, SA, Hart, GK, Bailey, MJ (2009) Landmark survival as an end-point for trials in critically ill patients 鈥?comparison of alternative durations of follow-up: an exploratory analysis. Crit Care 13: pp. R128 CrossRef
46. McGee, DC, Gould, MK (2003) Preventing complications of central venous catheterization. N Engl J Med 348: pp. 1123-1133 CrossRef
47. Basic-Jukic, N, Kes, P, Glavas-Boras, S, Brunetta, B, Bubic-Filipi, L, Puretic, Z (2005) Complications of therapeutic plasma exchange: experience with 4857 treatments. Ther Apher Dial 9: pp. 391-395 CrossRef - 刊物主题：Intensive / Critical Care Medicine; Emergency Medicine;
- 出版者：BioMed Central
- ISSN：1364-8535
文摘
Introduction Sepsis and septic shock are leading causes of intensive care unit (ICU) mortality. They are characterized by excessive inflammation, upregulation of procoagulant proteins and depletion of natural anticoagulants. Plasma exchange has the potential to improve survival in sepsis by removing inflammatory cytokines and restoring deficient plasma proteins. The objective of this study is to evaluate the efficacy and safety of plasma exchange in patients with sepsis. Methods We searched MEDLINE, EMBASE, CENTRAL, Scopus, reference lists of relevant articles, and grey literature for relevant citations. We included randomized controlled trials comparing plasma exchange or plasma filtration with usual care in critically ill patients with sepsis or septic shock. Two reviewers independently identified trials, extracted trial-level data and performed risk of bias assessments using the Cochrane Risk of Bias tool. The primary outcome was all-cause mortality reported at longest follow-up. Meta-analysis was performed using a random-effects model. Results Of 1,957 records identified, we included four unique trials enrolling a total of 194 patients (one enrolling adults only, two enrolling children only, one enrolling adults and children). The mean age of adult patients ranged from 38 to 53聽years (n鈥?鈥?28) and the mean age of children ranged from 0.9 to 18聽years (n鈥?鈥?6). All trials were at unclear to high risk of bias. The use of plasma exchange was not associated with a significant reduction in all-cause mortality (risk ratio (RR) 0.83, 95% confidence interval (CI) 0.45 to 1.52, I2 60%). In adults, plasma exchange was associated with reduced mortality (RR 0.63, 95% CI 0.42 to 0.96; I2 0%), but was not in children (RR 0.96, 95% CI 0.28 to 3.38; I2 60%). None of the trials reported ICU or hospital lengths of stay. Only one trial reported adverse events associated with plasma exchange including six episodes of hypotension and one allergic reaction to fresh frozen plasma. Conclusions Insufficient evidence exists to recommend plasma exchange as an adjunctive therapy for patients with sepsis or septic shock. Rigorous randomized controlled trials evaluating clinically relevant patient-centered outcomes are required to evaluate the impact of plasma exchange in this condition.